What is Halozyme Therapeutics's PP&E (net)?

Halozyme Therapeutics (HALO) reported PP&E (net) of $46.93M in Q1 2026.

How has Halozyme Therapeutics's PP&E (net) changed year-over-year?

Halozyme Therapeutics's PP&E (net) increased by 16.7% year-over-year, from $40.22M to $46.93M.

What is the long-term trend for Halozyme Therapeutics's PP&E (net)?

Over 5 years (2020 to 2025), Halozyme Therapeutics's PP&E (net) has grown at a 43.5% compound annual growth rate (CAGR), from $7.29M to $44.44M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

Halozyme Therapeutics HALO PP&E (Net)

PP&E (Net) at other companies

West Pharmaceutical ServicesWST

$1.7B+4.3%

BridgeBio PharmaBBIO

$4.94M-26.2%

Arrowhead ResearchARWR

$374.82M-2.6%

AptarGroupATR

$1.66B+11.5%

AbbVieABBV

$5.69B+8.6%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

See full

Revenue$376.7M+42.2%

Gross profit$297.5M+37.4%

Operating income$184.5M+30.4%

Net income$150.0M+27.1%

EPS (diluted)$1.22+31.2%

Balance sheet

See full

Cash & equivalents$312.0M+76.9%

Total debt$2.2B+41.7%

Total equity$219.6M-54.5%

Total assets$2.7B+21.7%

Cash flow

See full

Operating cash flow$180.1M+16.8%

CapEx$3.7M+294%

Free cash flow$176.3M+15.0%

Valuation

See full

Market cap$8.13B-2.9%

Enterprise value$10B+3.0%

P/E13.4×-3.8×

P/S5.4×-2.3×

Profitability

See full

Gross margin82.8%-0.7pp

Operating margin59.3%+9.0pp

Net margin47.9%+6.5pp

FCF margin44.3%-1.5pp

Returns & leverage

See full

Return on equity124.5%+12.7pp

Debt / equity9.9×+6.7×

Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Halozyme Therapeutics's PP&E (net)?: Halozyme Therapeutics (HALO) reported PP&E (net) of $46.93M in Q1 2026.
How has Halozyme Therapeutics's PP&E (net) changed year-over-year?: Halozyme Therapeutics's PP&E (net) increased by 16.7% year-over-year, from $40.22M to $46.93M.
What is the long-term trend for Halozyme Therapeutics's PP&E (net)?: Over 5 years (2020 to 2025), Halozyme Therapeutics's PP&E (net) has grown at a 43.5% compound annual growth rate (CAGR), from $7.29M to $44.44M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.